Value through Innovation01 December 2015
  • Home
  • Research & Development

Our Strategic Focus in Research & Development

Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.

More than 8,000 highly qualified people of Boehringer Ingelheim’s over 47,700 employees worldwide work at either one of our three major research & development sites (Biberach and Ingelheim, Germany, Ridgefield, USA, and Vienna, Austria) or two support centres (Kobe, Japan and Milan, Italy).

Currently, we work on more than 100 projects in our research organization. In 2014 our R&D spending reached 2.7 billion Euro which represents about 20 % of our net sales. Boehringer Ingelheim has a long-standing reputation in supporting basic science in academia. During the past decade, from 2005 to 2014, we conducted or sponsored 1,414 studies with 115 compounds in 95 countries from all regions of the world.

We are striving to expand our international network of academic, industry and not-for-profit partners who share our goal to meet the medical needs of the patients – We think together we can improve the health of people around the world. Currently, more than 50% of our early-mid stage pipeline is filled with products that are derived from external innovation with our partners.

Research & Development in detail

  • Discovery Research Areas

    Our new discovery research strategy aims at enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need. It is based on our three strategic pillars which are the Discovery Research Therapeutic Areas, Immune Modulation and NBE Discovery and the newly created Research Beyond Borders unit.

  • Research & Development Centres

    Boehringer Ingelheim conducts research and development of drugs in five locations. Germany is the largest research and development facility in the business association of Boehringer Ingelheim.

  • Drug Discovery

    From the first study of a drug to a marketable drug is a long and challenging journey. It takes an average of twelve years from the beginning of the research to the approved drug.

  • Awards & Fellowships

    Promoting basic research is a prerequisite to Boehringer Ingelheim's research & development mission and an integral part of our social responsibility.

  • Scientific Publications

    Overview of all publications of the last three years (YTD) where employees of Boehringer Ingelheim worldwide were involved.

Oncology Websites

No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player

Research & Development

Research & Development